News

Centralized systems are likely to be the most efficient way to increase colorectal cancer screening, according to a trial published in the March 5 Annals of Internal Medicine.

FDA voted 2-12 against approval for an investigational, oral, twice-daily formulation of gabapentin (Sefelsa, Depomed) to treat moderate to severe vasomotor symptoms due to menopause.

FDA has issued a second complete response letter regarding a supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto, Janssen) for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS).

A new study led by a researcher at the Perelman School of Medicine at the University of Pennsylvania adds support to current medical recommendations stating that screening colonoscopy substantially reduces an average-risk adult’s likelihood of being diagnosed with advanced colorectal cancer (CRC) in either the right or left side of the colon.

The 2012/2013 seasonal influenza vaccine is moderately effective at preventing medically attended influenza. However, some vaccinated people may still become infected, so clinicians should use antivirals as recommended by CDC regardless of vaccination status, according to estimates published in Morbidity and Mortality Weekly Report (MMWR), February 22, 2013.

Workers are changing their plans less often because they're offered fewer options from their employers

Inexpensive pill boxes could help at-risk members remain adherent to drug regimens and help WellPoint earn a higher star rating

Chronic care patients need reminder calls to remain adherent to treatment and show up for appointments

Reduce readmissions

Plans must offer non-clinical resources to help hospitals make successful transitions

Sirturo (Bedaquiline)

New molecular entity: Late last year FDA approved bedaquiline tablets for the treatment of pulmonary multi-drug-resistant tuberculosis (MDR-TB).

Allergy season is almost upon us and anti-histamine agents remain the top choice. However, researchers are looking for new medications to help patients with different needs.

Pipeline Preview

Recent FDA action (through February 2013) related to, rintatolimod, insulin degludec, insulin degludec/insulin aspart, dolutegravir, Radium-223 dichloride, APG101, LG631-CD34, Placental eXpanded, buprenorphine hydrochloride, naloxone HCI dihydrate, doxorubicin hydrochloride, clindamycin in 5% dextrose, Adderall

Recent FDA Approvals (through February 2013) related to (Ado-trastuzumab, Kadcyla, Genentech, Everolimus, Zortress, Novartis, Adapalene, benzoyl peroxide, Epiquo, Galderma, pomalidomide, Pomalyst, Celgene, alogliptin, Nesina, Takeda Pharmaceuticals, Kazano, Oseni, imatinib, Gleevec, mesalamine, Delzicol, Warner Chilcott, mipomersen sodium, Kynamro, Genzyme, Isis Pharmaceuticals, Merck, Oxutrol for Women, glycerol phenylbutyrate, Ravicti, Hyperion Therapeutics, pneumococcal 13-valent Conjugate Vaccine, Prevnar 13, Pfizer

Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder in children. New formulations of stimulants and nonstimulants allow for individualization of therapy for patients to receive the maximum benefit while minimizing side effects.